Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Revenue
Cosmos Health's pharmaceutical distribution subsidiary CosmoFarm posted record Q2 2026 revenue above $15 million, a $60 million+ annualized run-rate, roughly 4.3x its pre-acquisition level with an ~18% CAGR since 2017. Growth is driven by daily-served pharmacies rising from ~100 to ~360 within a 1,500+ pharmacy network, with revenue per daily customer up ~19%; 2025 revenue per customer rose ~12% and profitability per customer ~14%, signaling operating leverage.
Key figures
- Product codes
- 32,000+
- Cagr since 2017
- 18%
- Capacity to support
- $100 million+ annualized revenue
- Guidance 2029 revenue
- 200600000
- Real estate fair value
- $15 million
- Daily served pharmacies
- 360
- Guidance 2029 net income
- 31000000
- Total network pharmacies
- 1,500+
- Cosmofarm q2 2026 revenue
- $15 million+
- Guidance 2029 gross profit
- 71200000
- Cosmofarm annualized run rate
- $60 million+
- Guidance 2029 adjusted ebitda
- 44200000
- Revenue growth multiple since acquisition
- 4.3x
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.